Mechanistic insights into anti-inflammatory and immunosuppressive effects of plant secondary metabolites and their therapeutic potential for rheumatoid arthritis.
Yuandani YuandaniIbrahim JantanEmil SalimAbdi Wira SeptamaKamal RullahFirzan NainuMohd Fadhlizil Fasihi Mohd AluwiTalhah Bin EmranMiah RoneyNur Aini KhairunnisaHalimah Raina NasutionMuh Fadhil As'adNur Farisya ShamsudinMaryam Aisyah AbdullahHaya Luthfiyyah Marwa RaniDiany Mahabbah Al ChairaNabila AuliaPublished in: Phytotherapy research : PTR (2024)
The anti-inflammatory and immunosuppressive activities of plant secondary metabolites are due to their diverse mechanisms of action against multifarious molecular targets such as modulation of the complex immune system associated with rheumatoid arthritis (RA). This review discussed and critically analyzed the potent anti-inflammatory and immunosuppressive effects of several phytochemicals and their underlying mechanisms in association with RA in experimental studies, including preliminary clinical studies of some of them. A wide range of phytochemicals including phenols, flavonoids, chalcones, xanthones, terpenoids, alkaloids, and glycosides have shown significant immunosuppressive and anti-inflammatory activities in experimental RA models and a few have undergone clinical trials for their efficacy and safety in reducing RA symptoms and improve patient outcomes. These phytochemicals have potential as safer alternatives to the existing drugs in the management of RA, which possess a wide range of serious side effects. Sufficient preclinical studies on safety and efficacy of these phytochemicals must be performed prior to proper clinical studies. Further studies are needed to address the barriers that have so far limited their human use before the therapeutic potential of these plant-based chemicals as anti-arthritic agents in the treatment of RA is fully realized.
Keyphrases
- rheumatoid arthritis
- anti inflammatory
- disease activity
- ankylosing spondylitis
- interstitial lung disease
- clinical trial
- systemic lupus erythematosus
- endothelial cells
- ms ms
- case control
- cell therapy
- mesenchymal stem cells
- risk assessment
- cell wall
- idiopathic pulmonary fibrosis
- study protocol
- combination therapy
- human health
- single molecule
- phase iii